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experience
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Summary Ploidy and cell proliferation determined by flow cytometry were assessed on colorectal cancers
from patients admitted to two Italian cancer research centres. A total of 181 patients were followed
prospectively for 4 years at the Istituto Regina Elena (IRE) of Rome and at the Istituto Nazionale Tumori
(INT) of Milan. Fresh (at the IRE) or frozen (at the INT) tumour material and similar procedures were used
for subsequent sample preparation. Similar frequencies of aneuploid tumours (63% vs 66%) and superim-
posable median DNA indices (1.6) were observed for the two case series. In both series, DNA ploidy was
generally unrelated to clinico-pathological factors, except for a higher frequency of aneuploid tumours in
Dukes' D (88%) than in Dukes' A stage (33%) in the IRE experience. DNA ploidy was a weak prognostic
indicator at 3 years but not at 4 years in the IRE case series, and it never exhibited a clinical relevance in the
INT experience. Conversely, multiploidy was an indicator of worse relapse-free and overall survival at 4 years
in the IRE and INT case series.
Flow cytometric (FCM) analysis of DNA content is routinely
used in several centres to obtain biological information of
prognostic and therapeutic relevance for various human
tumour types. In particular, FCM analysis has been exten-
sively used in colorectal cancer to evaluate ploidy (Bauer et
al., 1987; Kouri et al., 1990; Quirke et al., 1987; Schutte et
al., 1987). Different frequencies of aneuploid tumours and
conflicting information on the prognostic relevance of ploidy
have been reported by different studies (Armitage et al., 1990;
Jass et al., 1989; Jones et al., 1988; Kokal et al., 1986; Kouri
et al., 1990; Quirke et al., 1987) and can be ascribed to
technical and biological reasons. One of the most crucial
points is the type of material used for FCM analysis.
Paraffin-embedded samples can involve interpretative prob-
lems owing to the lack of an internal standard and the
sometime poor quality of DNA histograms due to a large
amount of debris (Cusick et al., 1990; Giaretti et al., 1991;
Hedley et al., 1989; Kallioniemi et al., 1988). Different pro-
tocols to obtain cell or nuclei suspensions from fresh or
frozen specimens had been used, but few studies have been
performed to verify the comparability of the different app-
roaches. Another critical point for comparison of results is
the heterogeneity of the case series studied in terms of stage,
treatment protocols and follow-up.
To verify the consistency of FCM information by different
laboratories and in the perspective to activate therapeutic
clinical protocols based on biological information, with the
present study we compared the results obtained at two
Italian cancer institutes. In particular, the study was directed
to comparatively analyse the relation between DNA ploidy
and clinico-pathological characteristics and to evaluate prog-
nostic relevance of the former parameter.
Materials and methods
Fresh operative tumour samples were collected from prev-
iously untreated patients who underwent surgical resection at
the Istituto Regina Elena (IRE) of Rome or at the Istituto
Nazionale Tumori (INT) of Milan during the period 1987 to
1990. The main clinico-pathological characteristics of the two
case series are reported in Table I. The tumours were
Table I Clinico-pathological characteristics of patients with
colorectal cancer recruited by two national cancer institutes
IREa INTb
No. of cases No. of cases
Case series
Sex
Male
Female
Age (median, years)
Site of primary
Right colon
Left colon
Rectum
Dukes' stage
A
B
C
D
71 110
42
29
61
60
50
60
18
26
27
5
31
21
14
37
47
26
12
46
30
22
Treatment
Surgery 55 75
Surgery + radiotherapy 12 15
Surgery + chemotherapy 4 20
ajstituto Regina Elena, Rome; bIstituto Nazionale Tumori, Milan.
classified as right sided, left sided or rectal. Clinico-
pathological staging was done according to an extension of
Dukes' scheme, which, in addition to Dukes' stages A, B and
C, defines tumours with distant organ metastases as stage D.
Most of the patients (72%) were subjected to surgery alone.
Radiotherapy or chemotherapy was used as adjuvant treat-
ment for the remaining cases.
All patients, after surgical treatment, were followed as
outpatients every 4 months for the first 2 years, every 6
months for the 3rd year, and yearly after the 5th year.
Periodic controls consisted of a physical examination, col-
onoscopy (yearly), abdominal ultrasonography (quarterly),
chest X-ray (semi-yearly) and blood test including serum
CEA and CA 19.9. CT scan or NMR was performed in case
of suspected local or distant recurrence.
Patients with Dukes' stages B or C rectal tumours received
postoperative adjuvant radiotherapy (50 Gy). About 10% of
patients entered a clinical protocol (trial EORTC 40871) and
were randomised to receive surgical treatment alone or in-
traportal perfusional chemotherapy with 5-fluorouracil for
the first 7 postoperative days.
Flow cytometric analysis of DNA content was performed
starting with fresh (at the IRE) or frozen (at the INT)
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Table II Flow cytometric analysis: comparison between the two
national cancer institutes
IRE, INT,
Rome Milan
Tissue sample Fresh Frozen
Suspension Mechanical Mechanical
preparation disaggregation disaggregation
Type of suspension Cells Nuclei
Fixation Cold
acetone-methanol
Staining Propidium iodide, Propidium iodide,
RNase RNase, Nonidet P40
Flow cytometer FACS 420 FACScan
tumour material, with minimal differences in the subsequent
procedures between the two Institutes, as reported in Table
II. From three to nine fragments taken from different areas
of the lesion were pooled for DNA analysis. Cell suspensions
were prepared immediately after tumour excision by mincing
the tissue in phosphate-buffered saline (PBS), pH 7.6, fol-
lowed by filtration through a nylon mesh (pore size, 160tim)
and fixation in a cold acetone-methanol (1:4, v/v) and PBS
solution. Nuclei suspensions were obtained by mincing thaw-
ed tumour material in PBS, followed by filtration through a
nylon mesh (pore size, 160 .tm). The sample was centrifuged
for 10 min at 1,500 g, and the pellet was resuspended in PBS
at 4°C. The number of cells or nuclei was counted at the
microscope, and the concentration was adjusted to approx-
imately 106 ml-'. The suspensions were run in duplicate, and
to one of them human peripheral lymphocytes were added as
an internal standard before staining. Samples were stained
for 20-30 min (at room temperature, IRE, and at 4°C, INT)
in a solution containing propidium iodide (50 lgml-') and
RNase (75 Ku ml', IRE, and 100 Ku ml-', INT). Nonidet
P40 (0.05%) was added to nuclei suspensions. Immediately
before flow cytometric analysis, the samples were passed
through a 40-nLm filter. A minimum of 30,000 events for each
sample was analysed by a FACS 420 (Becton Dickinson,
Mountain View, CA, USA) or a FACScan (Becton Dickin-
son, San Jose, CA, USA) flow cytometer in a single-
parameter, 256-channel, integrated fluorescence histogram.
Table III DNA ploidy in primary colorectal cancer: experiences of
two national cancer institutes
IRE, Rome INT, Milan
(n= 71) (n= 110)
Aneuploidy 63% 66%
DNA index, median 1.6 1.6
(range) (1.1-2.3) (0.9-2.8)
Multiploidy 17% 12%
Table IV DNA ploidy in relation to clinico-pathological
characteristics of primary colorectal cancer
Incidence (%) of aneuploidy
IRE, INT,
Rome Milan
Site of primary
Right colon 52 51
Left colon 67 70
Rectum 60 80
Dukes' stage
A 33 83
B 67 59
C 48 70
D 88 68
Histology
Adenocarcinoma:
Well differentiated 63 63
Moderately/poorly differentiated 67 69
Mucinous 40 56
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Figure 1 Relapse-free and overall survival in diploid (broken
line) and aneuploid (solid line) tumours: INT, Milan experience.
The mean coefficient of variation of the diploid peak was
5% (range, 3.5-7.8%) in the IRE series and 3.5% (range,
2.7-6.5%) in the INT series. DNA ploidy was defined as
DNA index (DI), i.e., as the ratio between the mean channel
number of the GO/, peak of tumour cells and that of lym-
phocytes. Tumours with a DNA index different from 1 were
considered to be aneuploid. When two cell populations were
present, the highest DNA index was used to define tumour
ploidy; when three or more cell populations were present, the
DNA index of the largest aneuploid population was chosen
as representative of the tumour.
Differences in DNA ploidy patterns among the various
clinico-pathological subsets were analysed by the chi-square
and the Wilcoxon rank-sum tests. The Bonferroni procedure
was adopted to test multiple comparisons. Relapse-free sur-
vival (RFS) and overall survival (OS) were computed, start-
ing from the date of surgery, by means of the Kaplan-Meier
(1958) product-limit method. The log rank test was used to
assess differences among subgroups.
The role of ploidy as a prognostic variable (univariate
analysis) was evaluated by resorting to a Weibull regression
model. In this model each regression coefficient (p) is recog-
nisable as the log of the hazard ratio and it is constant in
time. For ploidy the unadjusted hazard ratio and its 95%
confidence interval were estimated according to a regression
model containing only that variable, by using the putative
best prognosis as reference category.
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Figure 2 Relapse-free and overall survival in diploid (broken
line) and aneuploid (solid line) tumours: IRE, Rome experience.
Results
Superimposable frequencies of aneuploid tumours (63% and
66% for the IRE and INT, respectively) and the same
median DI value (1.6) were observed for the two case series,
irrespective of whether fresh or frozen tumour material was
used. Multiploid tumours were present in 17% and 12% of
the IRE and INT series, respectively (Table III).
DNA ploidy was analysed in relation to site of the primary
tumour, Dukes' stage and histological grade (Table IV). No
significant relation was observed between DNA ploidy of the
primary tumour and any of the considered variables in either
of the case series. However, a higher frequency of aneuploid
tumours was observed in Dukes' stage D than in Dukes'
stage A tumours (88% vs 33%) in the IRE case series.
The clinical outcome of patients in the two case series was
analysed as a function of DNA ploidy. RFS and OS curves
for patients with diploid or aneuploid tumours were superim-
posable in the Milan experience (Figure 1). In the IRE
experience, slightly better (not statistically significant) RFS
and OS were observed during the first 3 years for patients
with diploid than for those with aneuploid tumours, but the
clinical outcome was similar at 4 years (Figure 2). Similar
findings were also reflected by the hazard ratios and their
confidence limits for INT and IRE series (Table V). No
additive prognostic information was obtained from a break-
down analysis as a function of various DI values and
different percentages of aneuploid cells (data not shown).
Conversely, we observed a significantly better RFS in both
IRE (78% vs 53%) and INT (55% vs 27%) series for patients
with tumours showing a normal DNA content or only one
aneuploid subpopulation than for patients with tumours
made up of more than one aneuploid subpopulation. Simi-
larly, OS was significantly better in the former than in the
latter group (69% vs 33% and 63% vs 35%, respectively)
(Figure 3). Hazard ratios and their confidence intervals are
also reported in Table V to provide a quantitative measure of
the effect of multiploid DNA content on RFS and OS. In
both the case series the probability of relapse and death was
higher for patients with multiploid tumours than for patients
with diploid or aneuploid tumours.
Discussion
Colorectal adenocarcinoma is estimated to have a high
incidence and mortality among all cancer diagnoses in both
sexes. Attempts to reduce mortality have taken many forms,
such as identification of patients at different risk for whom
there is the necessity to consider the role and the modality of
adjuvant treatments. Numerous studies have verified the
clinical utility of stage at diagnosis as the single most impor-
tant prognostic indicator (Wiggers et al., 1988).
However, considering the results obtained for other human
tumour types, it could be supposed that biological charac-
teristics, such as DNA ploidy, can give additional inform-
ation to integrate with clinical or pathological staging. For
colorectal cancer, the prognostic relevance of ploidy has not
been consistently demonstrated by different studies, and the
disagreement can be ascribed to heterogeneity of FC proce-
dures, interpretation of results, and the case series analysed.
In thisjoint study of two national cancer institutes in Italy,
superimposable results were independently obtained. The fre-
quencies of aneuploid tumours in the two case series are in
accord with the highest values reported in the literature, thus
indicating that no aneuploid cell populations were lost during
methodological manipulations, and even near-diploid popula-
tions were detected. Comparability of results was possible
owing to the similar distributions of tumours in the different
Table V Univariate analysis of 4-year follow-up
Relapse Death
Hazard ratio Hazard ratio
(95% CL) pa (95% CL) pa
Aneuploid vs diploidb
INT, Milan 1.07 nsC 1.20 ns
(0.53-2.12) (0.56-2.56)
IRE, Rome 2.08 ns 1.48 ns
(0.66-2.49) (0.69-3.16)
Multiploid vs diploid or aneuploidb
INT, Milan 3.12 0.008 3.24 0.01
(1.34-7.27) (1.30-8.04)
IRE, Rome 5.47 0.007 2.53 0.055
(1.60-8.73) (0.97-6.62)
aWald statistics. bReference category. cns, not significant.
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Figure 3 Relapse-free a, b, and overall survival c, d, evaluated on series of primary colorectal cancers from two national cancer
institutes (broken line, diploid or aneuploid; solid line, multiploid).
Dukes' stages, the similar patient treatment, and the careful
follow-up through periodic clinical and instrumental examin-
ations by both the institutes.
In our multicentric study, DNA ploidy, different DI
values, and percentage of aneuploid cells were all unable to
identify subgroups of patients with different risks of relapse
or death, in agreement with the results reported by Kouri et
al. (1990) and Rognum et al. (1987) at a similar 4-year
follow-up. Conversely, our data are in disagreement with
most reported results of several studies with a longer follow-
up (Armitage et al., 1990; Harlow et al., 1991; Rognum et
al., 1991). Such results appear to indicate that DNA ploidy
could be a late indicator of survival, and this hypothesis is
supported by the appearance of a prognostic relevance of
DNA ploidy at 5 years (Rognum et al., 1991) in the same
series of patients in which clinical relevance had not been
detected at a shorter follow-up (Rognum et al., 1987). The
long time required for DNA ploidy to exhibit its impact on
survival is probably due to the limitation of a prognostic
relevance to Dukes' stages A, B and C. Conversely, our
results showed, for the first time in colorectal cancer, that
multiploidy represents an early and eventually unfavourable
prognostic factor.
In any case, in view of the biological heterogeneity of
colorectal cancer, further analyses on subgroups of patients
defined according to the most important prognostic factors,
such as Dukes' stage, site of the primary and type of treat-
ment, could even more accurately identify very high-risk
patient groups.
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